Skip to Content

'
Jeri Kim, M.D.

Present Title & Affiliation

Primary Appointment

Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Bio Statement

Fundamental to my research is a clinical framework for studying low-volume prostate cancer to delineate underlying molecular mechanisms involved in prostate carcinogenesis and disease progression. I have been a Principal Investigator (PI) or Co-investigator for studies funded by the NCI, grants from private nonprofit groups, and internal grants—and perspective that best comes from experience: “dual citizenship” in clinical medicine and basic science. I have expanded my technical expertise in laser capture microdissection, oligonucleotide microarrays, and immunohistochemical studies (NCI-funded [R21 and R03] studies of prostate cancer multifocality); managed both clinical and tissue studies in an examination of the Prostate Cancer Prevention Trial finding of higher grade cancers in men taking finasteride (as PI of an N01 trial); and led tissue and clinical studies in a longitudinal study of early-stage prostate cancer in one of the largest active surveillance cohorts in the world (as PI). Building a multidisciplinary team of collaborators—pathologists, surgeons, biostatisticians, and oncologists—over time has streamlined operations, benefiting team members, the students who engage in the work, and the translations to improve clinical practice that we are attempting.

Education & Training

Degree-Granting Education

1993 University of Southern California, Keck School of Medicine, Los Angeles, CA, MD, Medicine
1988 University of California Los Angeles, Los Angeles, CA, BS, Biochemistry

Postgraduate Training

7/1996-7/1999 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
6/1994-6/1996 Clinical Residency, Internal Medicine, Baylor College of Medicine, Houston, TX
6/1993-6/1994 Clinical Internship, Internal Medicine, Baylor College of Medicine, Houston, TX

Board Certifications

2006 Medical Oncology
1996 American Board of Internal Medicine

Experience/Service

Academic Appointments

Associate Member, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, 9/2010-present
Member, The University of Texas Graduate School of Biomedical Sciences at Houston, Houston, TX, 8/2006-8/2010
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 1999-2005

Other Appointments/Responsibilities

Member, American Society of Clinical Oncology, Cancer Education Committee, Cancer Prevention/Epidemiology Track, Chicago, IL, 6/2013-6/2016

Institutional Committee Activities

Steering Committee Member, Division of Cancer Medicine Hematology/Oncology Fellowship Program, 7/2014-present
Director, Department of Genitourinary Medical Oncology Research Biorepository, 1999-present

Honors and Awards

2013 Incentive Salary Award
2005 Participation in AACR Task Force on Prevention Meeting
2004 Incentive Salary Award
2001-2004 Clinician Investigator Program Career Development Award
2001 Institutional Research Grant Award
1998 Clinical Fellows Research Award
1998 Participation in ASCO/AACR Methods in Clinical Cancer Research, Third Annual Workshop
1997 Clinical Fellows Research Award
1996-1997 Clifton D. Howe Award for Clinical Excellence
1990-1991 Fifth Year Research Scholar, Experimental Cutaneous Injury Due to Hydrofluoric Acid
1987 National Science Foundation Summer Research Fellowship: Organic Chemistry
1984-1988 Dean's Honor List, University of California, Los Angeles

Selected Publications

Peer-Reviewed Original Research Articles

1. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Stephenson A, Li Ning Tapia EM, Efstathiou E, Wang X, Do KA, Lee JJ, Gorlov IP, Vornik LA, Hoque AM, Prokhorova IN, Parnes HL, Lippman SM, Thompson IM, Brown PH, Logothetis CJ,* Troncoso P* (co-last authors). Tissue effects in a randomized controlled trial of short-term finasteride in early prostate cancer (co-last authors). eBioMedicine. In Press.
2. Shu X, Ye Y, Gu J, He Y, W Davis J, C Thompson T, J Logothetis C, Kim J, Wu X. Genetic variants of the Wnt signaling pathway as predictors of aggressive disease and reclassification in men with early stage prostate cancer on active surveillance. Carcinogenesis. e-Pub 8/2016. PMID: 27515962.
3. Davis JW, Ward JF, Pettaway CA, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim M, Hoffman KE, Pugh TJ, Choi S, Troncoso P, Logothetis CJ, Kim J. Disease reclassification risk with stringent criteria and frequent monitoring in men with favourable-risk prostate cancer undergoing active surveillance. BJU Int 118(1):68-76, 7/2016. e-Pub 7/2015. PMCID: PMC4808616.
4. Karantanos T, Karanika S, Wang J, Yang G, Dobashi M, Sanghee Park S, Ren C, Li L, Basourakos SP, Hoang A, Efstathiou E, Wang X, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC. Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer. Oncotarget. e-Pub 6/2016. PMID: 27331874.
5. Kalra S, Basourakos S, Abouassi A, Achim M, Volk RJ, Hoffman KE, Davis JW, Kim J. The implications of ageing and life expectancy in prostate cancer treatment. Nat Rev Urol 13(5):289-95, 5/2016. e-Pub 3/2016. PMID: 27001016.
6. Parker PA, Davis JW, Latini DM, Baum G, Wang X, Ward JF, Kuban D, Frank SJ, Lee AK, Logothetis CJ, Kim J. The Relationship Between Illness Uncertainty, Anxiety, Fear of Progression, and Quality of Life in Men With Favorable Risk Prostate Cancer Undergoing Active Surveillance. BJU Int 117(3):469-77, 3/2016. e-Pub 4/21/2015. PMCID: PMC4547910.
7. Tu H, Gu J, Meng QH, Kim J, Davis JW, He Y, Wagar EA, Thompson TC, Logothetis CJ, Wu X. Mitochondrial DNA copy number in peripheral blood leukocytes and the aggressiveness of localized prostate cancer. Oncotarget 6(39):41988-96, 12/8/2015. e-Pub 10/26/2015. PMID: 26515605.
8. Mintz PJ, Rietz AC, Cardó-Vila M, Ozawa MG, Dondossola E, Do KA, Kim J, Troncoso P, Logothetis CJ, Sidman RL, Pasqualini R, Arap W. Discovery and horizontal follow-up of an autoantibody signature in human prostate cancer. Proc Natl Acad Sci U S A 112(8):2515-20, 2/24/2015. e-Pub 2/9/2015. PMCID: PMC4345585.
9. He Y, Gu J, Strom S, Logothetis CJ, Kim J, Wu X. The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify Gleason Score 7 patients (*co-last authors). Clin Cancer Res 21(3):5133-9, 10/1/2014. PMCID: PMC4185411.
10. Hoffman KE, Niu J, Shen Y, Jiang J, Davis JW, Kim J, Kuban DA, Perkins GH, Shah JB, Smith GL, Volk RJ, Buchholz TA, Giordano SH, Smith BD. Physician variation in management of low-risk prostate cancer: a population-based cohort study. JAMA Intern Med 174(9):1450-9, 9/2014. PMCID: PMC4372187.
11. Madsen LT, Kuban DA, Choi S, Davis JW, Kim J, Lee AK, Domain D, Levy L, Pisters LL, Pettaway CA, Ward JF, Logothetis C, Hoffman KE. Impact of a Clinical Trial Initiative on Clinical Trial Enrollment in a Multidisciplinary Prostate Cancer Clinic. J Natl Compr Canc Netw 12(7):993-8, 7/2014. PMCID: PMC4413899.
12. Cohen T, Widdows D, Stephan C, Zinner R, Kim J, Rindflesch T, Davies P. Predicting High-throughput screening results with scalable literature-based discovery methods. CPT Pharmacometrics Syst Pharmacol 3(10):1-10, 2014. e-Pub 10/8/2014. PMCID: PMC4474167.
13. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov 3(8):849-61, 8/2013. e-Pub 6/28/2013. PMCID: PMC3926428.
14. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 19(13):3621-30, 7/1/2013. e-Pub 5/6/2013. PMCID: PMC3699964.
15. Bilen MA, Kim J, Wang H, Tu SM. Cituxumumab-associated pancolitis in a patient with prostate cancer. Clin Genitourin Cancer 11(2):207-10, 6/2013. e-Pub 10/17/2012. PMCID: PMC3579009.
16. Kim J, Ebertowski J, Janiga M, Arzola J, Gillespie G, Fountain M, Soderdahl D, Canby-Hagino E, Elsamanoudi S, Gurski J, Davis JW, Parker PA, Boyd DD. Many young men with prostate-specific antigen (PSA) screen-detected prostate cancers may be candidates for active surveillance. BJU Int 111(6):934-40, 5/2013. e-Pub 1/25/2013. PMCID: PMC3637421.
17. Yang P, Cartwright CA, Li J, Wen S, Prokhorova IN, Shureiqi I, Troncoso P, Navone NM, Newman RA, Kim J. Arachidonic acid metabolism in human prostate cancer. Int J Oncol 41(4):1495 - 1503, 10/2012. e-Pub 8/10/2012. PMCID: PMC3982713.
18. Kim J, Davis JW. Prostate cancer screening--time to abandon one-size-fits-all approach? JAMA 306(24):2717-8, 12/28/2011. PMID: 22203541.
19. del Junco DJ, Fox EE, Cooper S, Goldhagen M, Koda E, Rogers D, Canby-Hagino E, Kim J, Pettaway C, Boyd DD. Increasing low risk prostate cancer incidence in United States Air Force Servicemen and Selection of Treatments. J Urol 185(6):2137-2142, 6/2011. e-Pub 4/15/2011. PMCID: PMC3171171.
20. Li J, Ding Z, Wang Z, Lu JF, Maity SN, Navone NM, Logothetis CJ, Mills GB, Kim J. Androgen regulation of 5α-reductase isoenzymes in prostate cancer: Implications for prostate cancer prevention. PLoS One 6(12):e28840, 2011. e-Pub 12/14/2011. PMCID: PMC3237548.
21. Davis JW, Kim J, Ward JF, Wang X, Nakanishi H, Babaian RJ, Troncoso P. Radical prostatectomy findings in patients with low-volume/low-risk prostate cancer diagnosed by extended core biopsies:an analysis of tumor volume and zonal distribution of tumour foci. BJU Int 105(10):1386-91, 5/2010. e-Pub 11/3/2009. PMID: 19888979.
22. Li J, Kim J. Molecular profiles of finasteride effects on prostate carcinogenesis. Cancer Prev Res (Phila) 2(6):518-24, 6/2009. e-Pub 6/2/2009. PMID: 19491289.
23. Blando J, Portis M, Benavides F, Alexander A, Mills G, Dave B, Conti CJ, Kim J, Walker CL. PTEN deficiency is fully penetrant for invasive prostate adenocarcinoma in C57B/6 mice. Am J Pathol 174(5):1869-79, 5/2009. PMCID: PMC2671275.
24. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stephens C, Efstathiou E, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Selenium and Vitamin E:Cell Type-and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst 101(5):206-20, 3/4/2009. e-Pub 2/24/2009. PMCID: PMC2734116.
25. Lin SH, Lee YC, Choueiri MB, Wen S, Mathew P, Ye X, Do KA, Navone NM, Kim J, Tu SM, Yu-Lee LY, Logothetis CJ. Soluble ErbB3 levels in bone marrow and plasma in men with prostate cancer. Clin Cancer Res 14(12):3729-36, 6/15/2008. PMCID: PMC2562877.
26. Jonasch E, Wood C, Tamboli P, Pagliaro LC, Tu SM, Kim J, Srivastava P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine:clinical finds. Brit J Cancer 98(8):1336-41, 3/2008. PMID: 18362942.
27. Lin SH, Cheng CJ, Lee YC, Ye X, Tsai WW, Kim J, Pasqualini P, Arap W, Navone NM, Tu SM, Hu M, Yu-Lee LY, Logothetis CJ. A 45-kDa ErbB3 secreted by prostate cancer cells promotes bone formation. Oncogene 27(39):5195-203, 2008. PMID: 18490922.
28. Mao S, Daliani DD, Wang X, Thall PF, Do KA, Perez CA, Brown MA, Bouchillon K, Carter CM, Logothetis CJ, Kim J. Employing the treatment-free interval of intermittent androgen ablation to screen candidate prostate cancer therapies. Prostate 67(15):1677-85, 11/1/2007. PMID: 17879948.
29. Cheng CJ, Ye XC, Vakar-Lopez F, Kim J, Tu SM, Chen DT, Navone NM, Yu-Lee LY, Lin SH, Hu MC. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells. Mol Cancer Res 5(7):675-84, 7/2007. PMCID: PMC2000833.
30. Subbarayan V, Krieg P, His LC, Kim J, Yang P, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. 15-lipoxygenase-2 (15-LOX-2) gene regulation by its product 15-S-hydroxyeicostatetraenoic acid through a negative feed back mechanism that involves peroxisome proliferators-activated receptor gamma. Oncogene 25(44):6015-25, 9/2006. PMID: 16682954.
31. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK, AACR Task Force on Cancer Prevention. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia (IEN) and cancer--a plan to move forward. Clin Cancer Res 12(12):3661-97, 6/15/2006. PMID: 16778094.
32. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Strontium-89 combined with chemotherapy does not compromise subsequent tharapy in selected patients with androgen-independent prostate cancer. J Clin Oncol 23(31):7904-10, 11/2005. PMID: 16258090.
33. Lee SH, Nishino M, Mazumdar T, Garcia GE, Galfione M, Lee FL, Lee CL, Liang A, Kim J, Feng L, Eissa NT, Lin SH, Yu-Lee LY. Antiangiogenic effect of 16-kDa prolactin involves the inhibition of the IRF-1 pathway that regulates iNOS expression. Cancer Res 65(17):7984-92, 9/1/2005. PMID: 16140971.
34. Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, Subbarayan V, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. Cancer Res 65(14):6189-98, 7/15/2005. PMID: 16024620.
35. Kim J*, Sun P*, Lam YW, Troncoso P, Sabichi AL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, McDonnell TJ, Lieberman R, Logothetis C, Ho SM. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer (*co-first authors). Cancer Epidemiol Biomarkers Prev 14(7):1697-1702, 7/2005. PMID: 16030104.
36. Subbarayan V, Xu XC, Kim J, Yang P, Hoque A, Sabichi AL, Llansa N, Mendoza G, Logothetis CJ, Newman RA, Lippman SM, Menter DG. Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia. Neoplasia 7(3):280-93, 3/2005. PMCID: PMC1501140.
37. Subbarayan V, Sabichi AL, Kim J, Llansa N, Logothetis CJ, Lippman SM, Menter DG. Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells. Cancer Epidemiol Biomarkers Prev 13(11 Pt 1):1710-6, 11/2004. PMID: 15533897.
38. Fizazi K, Sikes CR, Kim J, Yang J, Martinez LA, Olive MC, Logothetis CJ, Navone NM. High efficacy of docetaxel with and without androgen deprivation and estramustine in preclinical models of advanced prostate cancer. Anticancer Res 24(5A):2897-903, Sep-Oct, 9/2004. PMID: 15517894.
39. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 22(11):2108-21, 6/1/2004. PMID: 15169797.
40. Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Troncoso P, Tu SM, Yu-Lee LY, Lin SH. Up-regulation of MDA-BF-1, a secreted isoform of ErbB3, in metastatic prostate cancer cells and activated osteoblasts in bone marrow. J Pathol 203(2):688-95, 6/2004. PMID: 15141384.
41. Salas TR, Kim J, Vakar-Lopez F, Sabichi AL, Troncoso P, Jenster G, Kikuchi A, Chen SY, Shemshedini L, Suraokar M, Logothetis CJ, DiGiovanni J, Lippman SM, Menter DG. Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity.(*co-first authors). J Biol Chem 279(18):19191-200, 4/30/2004. e-Pub 2/24/2004. PMID: 14985354.
42. Tu SM, Millikan RE, Pagliaro LC, Daliani D, Papandreou CN, Kim J, Chen DT, Williams DL, Logothetis CJ. Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP). Urol Oncol 21(5):342-8, Sep-Oct, 9/2003. PMID: 14670540.
43. Galfione M, Luo W, Kim J, Hawke D, Kobayashi R, Clapp C, Yu-Lee LY, Lin SH. Expression and purification of the angiogenesis inhibitor 16-kDa prolactin fragment from insect cells. Protein Expr Purif 28(2):252-8, 4/2003. PMID: 12699689.
44. Kim J, Luo W, Chen DT, Earley K, Tunstead J, Yu-Lee LY, Lin SH. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer. Cancer Res 63(2):386-93, 1/15/2003. PMID: 12543792.
45. Mintz PJ, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2(1):57-63, 1/2003. e-Pub 12/2002. PMID: 12496764.
46. Kim J, Millikan RE, Smith TL, Tu SM, Pagliaro LC, Logothetis CJ. Treating refractory advanced or metastatic urothelial carcinoma with interleukin-2: a phase II study. Urol Oncol 21(1):21-6, Jan-Feb, 1/2003. PMID: 12684123.
47. Zinner RG, Kim J, Herbst RS. Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results. Lung Cancer 37(1):17-27, 7/2002. PMID: 12057863.
48. Fizazi K, Prow DM, Do KA, Wang X, Finn L, Kim J, Daliani D, Papandreou CN, Tu SM, Millikan RE, Pagliaro LC, Logothetis CJ, Amato RJ. Alternating dose-dense chemotherapy in patients with high volume disseminated non-seminomatous germ cell tumours. Br J Cancer 86(10):1555-60, 5/2002. PMID: 12085204.
49. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagilaro LC, Dailani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate:a randomized phase II trial. Lancet 357:336-41, 2001. PMID: 11210994.
50. Kim J, Palmer JL, Finn L, Hodges S, Bowes VV, Deftos L, Murphy G, Logothetis C. The pattern of serum markers in patients with androgen-independent adenocarcinoma of the prostate. Urol Oncol 5(3):97-103, 4/2000. PMID: 10765015.
51. Newman RA, Kim J, Newman BM, Bruno R, Bayssas M, Klink-Alaki M, Pazdur R. Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors. Anticancer Drugs 10(10):889-94, 11/1999. PMID: 10630356.
52. Kim J, Logothetis CJ. Serologic tumor markers, clinical biology, and therapy of prostatic carcinoma. Urol Clin North Am 26(2):281-90, 5/1999. PMID: 10361551.
53. Kim J, Zhi J, Satoh H, Koss-Twardy SG, Passe SM, Patel IH, Pazdur R. Pharmacokinetics of recombinant human interferon-alfa 2a combined with 5-fluorouracil in patients with advanced colorectal carcinoma. Anticancer Drugs 9(8):689-96, 9/1998. PMID: 9823427.
54. Hjelle B, Goade D, Torrez-Martinez N, Lang-Williams M, Kim J, Harris RL, Rawlings JA. Hantavirus pulmonary syndrome, renal insufficiency, and myositis associated with infection by Bayou hantavirus. Clinical Infect Dis 23(3):495-500, 9/1996. PMID: 8879771.
55. Kim J, Weibel TJ, Calobrace MD, Foldi JF, Zawacki BE. A standard experimental 'Chemical Burn'. Burns 20(3):200-1, 6/1994. PMID: 8054129.
56. Wheeler HE, Gamazon ER, Frisina RD, Perez-Cervantes C, El Charif O, Fossa SD, Feldman DR, Hamilton R, Vaughn DJ, Beard CJ, Fung C, Einhorn LH, Kollmannsberger C, Kim J, Mushiroda T, Kubo M, Ardeshir-Rouhani-Fard S, Cox NJ, Dolan ME, Travis LB. Genome-wide association study with replication implicates WFS1 in cisplatin-associated hearing loss and reveals an enrichment of SNPs in Mendelian genes for deafness. Multi-center Platinum Study Group. Submitted.
57. Tu H, Gu J, Meng Q, Kim J, Strom S, Davis JW, He Y, Wagar EA, Thompson T, Logothetis CJ, Wu X. Low serum testosterone is associated with aggressive prostate cancer and poor prognosis. Submitted.

Invited Articles

1. Li J, Amos CJ, Kim J. Role of 5a-reductase in prostate cancer prevention. Uro Today, 2012.
2. Kim J, Parker P, Boyd D. Should the low participation rate of young (less than 56 years) men with clinically insignificant prostate cancer in active surveillance be increased? Uro Today, 2011.
3. Zinner RG, Kim J, Herbst RS. Trastuzumab enters non-small cell lung cancer clinical trials. Her2 in Oncol 1(3):2-11, 2000.

Editorials

1. Kim J. Chemoprevention of prostate cancer: breakthroughs and controversies. Expert Rev Anticancer Ther 10(10):1517-22, 10/2010. PMID: 20942621.
2. Efstathiou E, Kim J, Logothetis CJ. Informative clinical investigation:a demanding task master. J Clin Oncol 27(30):4986-93, 10/20/2009. e-Pub 8/31/2009. PMID: 19720892.
Other Articles
1. Kim J, Davis JW. Recommendations on use of prostate-specific antigen for prostate cancer screening - Reply. JAMA(307):1373, 2012.

Abstracts

1. Corn PG, Tu SM, Zurita AJ, Subudhi SK, Araujo JC, Kim J, Jonasch E, Pagliaro LC, Siefker-Radtke AO, Wang J, Wang X, Health EI, Logothetis C, Aparicio A. A Multi-institutional Randomized Phase II Study (NCT01505868) of Cabazitaxel (CAB) plus or minus Carboplatin (CARB) in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC). J Clin Oncol (#5010). In Press.
2. Wheeler HE, Gamazon ER, Frisina RD, Perez-Cervantes C, El Charif O, Fossa SD, Feldman DR, Hamilton R, Vaughn DJ, Beard CJ, Fung C, Einhorn LH, Kollmannsberger C, Kim J, Mushiroda T, Kubo M, Ardeshir-Rouhani-Fard S, Cox NJ, Dolan ME, Travis LB. Genome-wide association study with replication implicates WFS1 in cisplatin-associated hearing loss and reveals an enrichment of SNPs in Mendelian genes for deafness. 2016 American Society of Human Genetics Meeting, 10/2016.
3. Thein KZ, Osai W, Tu SM, Pagliaro LC, Kim J, Yeung SJ. Association between abdominal adiposity, low muscle mass, and metabolic syndrome in testicular germ cell survivors. ASCO 2016 Palliative Care in Oncology Symposium (#250), 9/2016.
4. Blanchard P, Davis J, Frank SJ, Kim J, Pettaway CA, Pugh TJ, Pisters LL, Mahmood UX, Ward JF, Choi S, Chapin BF, Hoffman K, Navai N, McGuire SE, Matin SF, Nguyen Q, Thaker NG, Chen HC, Wang X, Kuban DA. How to counsel patients with localized prostate cancer about treatment selection? Quality of life results of a prospective single institution cohort. ASTRO 58th Annual Meeting, 9/2016.
5. Spyridon P Basourakos, John W. Davis, Brian Francis Chapin, John Francis Ward, Curtis Alvin Pettaway, Louis L. Pisters, Mary F. Achim, Xuemei Wang, Seungtaek Choi, Deborah A. Kuban, Patricia Troncoso, Christopher Logothetis, Timothy C. Thompson, Jeri Kim. Plasma caveolin-1 to predict disease reclassification in men with early stage prostate cancer in active surveillance. J Clin Oncol 34(suppl; abstr 5052), 6/2016.
6. Mehmet Asim Bilen, Diana H. Cauley, Bradley J. Atkinson, Hsiang-Chun Chen, Diana Kaya, Xuemei Wang, Raghu Vikram, Shi-Ming Tu, Paul Gettys Corn, Jeri Kim. Safety of same-day pegfilgrastim administration and incidence of cystitis and ureteritis in mCRPC treated with cabazitaxel ± carboplatin. J Clin Oncol 34(suppl; abstr e16513), 6/2016.
7. Troncoso P, Davis JW, Li Ning Tapia E, Prokhorova I, Ward JF, Pisters LL, Achim M, Logothetis CJ, Kim J. Prostate Cancer Gleason Grade 4 Pattern Heterogeneity in Men on Active Surveillance who Undergo Delayed Prostatectomy. 105th United States & Canadian Academy of Pathology Annual Meeting, 3/2016.
8. Basourakos SP, Karantanos T, Karanika S, Wang J, Yang G, Park S, Ren C, Li L, Hong A, Efstathiou E, Troncoso P, Titus M, Broom B, Kim J, Corn PG, Logothetis CJ, Thompson TC. Caveolin-1 regulates castration resistance through lipid synthesis: tumor-derived biomarkers in metastatic castration-resistant prostate cancer. 26th International Prostate Cancer Update Meeting, 1/2016.
9. Davis JW, Achim M, Ward JF, Pettaway CA, Chapin BF, Wang X, Kuban D, Frank SJ, Lee AK, Pisters LL, Matin SF, Shah JB, Karam JA, Papadopoulos J, Karen Hoffman KE, Pugh TJ, Choi S, Logothetis CJ, Troncoso P, Kim J. Active surveillance in men with phenotypically heterogeneous early stage prostate cancer. J Clin Oncol 32 (#(suppl; abstr 5083)), 2014.
10. Parker PA, Davis JW, Latini D, Baum G, Wang X, Ward JF, Kuban DA, Frank SJ, Lee A, Logothetis C, Kim J. Associations between uncertainty, anxiety, and quality of life in men with favorable-risk prostate cancer on active surveillance: A 2.5 year follow-up. J Clin Oncol 32 (suppl 4) (#135), 2014.
11. Oh J, Davis J, Hoffman K, Wen S, Kim J. Significance of Age and Comorbidity in Management Decision-Making in Early Prostate Cancer. Poster Presentation, International MASCC/ISOO Symposium, 2014.
12. Bilen MA, Hess KR, Aparicio A, Kim J, Zurita AJ, Pagliaro LC, Araujo JC, Corn PG, Atkinson BJ, Tannir NM, Sharma P, Lin SH, Logothetis C, Tu SM. Sipuleucel-T cellular immunotherapy: Clinical predictors of survival in patients with castration-resistant prostate cancer (CRPC). J Clin Oncol 32 (#e16046), 2014.
13. Kim J, Ward JF, Pettaway CA, Wang S, Kuban DA, Frand SF, Lee A, Pisters LL, Matin SF, Shah JB, Karam JA, Chapin BF, Papadopoulos JN, Achim BF, Hoffman KE, Pugh TJ, Choi S, Logothetis C, Troncoso P, Davis JW. Risk of Missing advanced stage or high grade tumors during active surveillance (AS) even in favorable-risk prostate cancer (PC). Journal of Clinical Oncology, 2013 ASCO Annual Meeting Proceedings, 5/2013.
14. Kim J, Davis JW, Klein EA, Magi-Galluzzi C, Lotan Y, Ward JF, Pisters LL, Basler JW, Pettaway CA, Li Ning Tapia EM, Wang X, Do KA, Lee J, Vornik LA, Tangrea J, Parnes HL, Lippman SM, Thompson IM, Brown PH, Troncoso P, Logothetis CJ. A double-blind randomized controlled multisite trial evaluating tissue effects of preoperative finasteride in clinically organ-confined prostate cancer: Pathologic outcomes. Proceedings of the 104th Annual Meeting of the American Association for Cancer Research abstr 195, 4/2013.
15. Li Ning Tapia E, Kim J, Efstathiou E, Wang X, Prokhorova I, Gorlov I, Amos C, Troncoso P. Linking markers of steroid metabolism, cell cycle and microenvironment to Gleason Score: Towards the development of a prognostic panel. USCAP, 3/2013.
16. Hoffman KE, Niu J, Shen Y, Jiang J, Shah JB, Smith GL, Davis JW, Kim J, Volk R, Kuban DA, Giordano SH, Smith BD. Does the diagnosing urologist influence choice of initial active treatment vs. observation for older men with favorable prostate cancer?. GU ASCO, 2/2013.
17. Oh JH, Davis JW, Hoffman KE, Wen S, Taylor SH, Doshi S, Jakkoju R, Suman S, Day R, Kim J. Significance of Age and Comorbidity in Management Decision-Making in Early Stage Prostate Cancer. Societe Internationale d'Urologie Oncology Update, 10/2012.
18. Parker P, Ebertwoski J, Janiga M, Arzola J, Fountain M, Canby-Hagino E, Kim J, Boyd DD. Evaluating the factors contributing to the high rate of definitive treatment in Department of Defense (DoD) personnel diagnosed with low-risk prostate cancer. MD Anderson Cancer Survivorship Research Retreat, 1/2012.
19. Ebertwoski J, Janiga M, Arzola J, Gillispie G, Fountain M, Soderdahl D, Davis J, Kim J, Boyd DD. Is a subset of prostate-specific antigen screen-detected, prostate cancers cases diagnosed in servicemen under 56 years candidate for active surveillance?. MD Anderson Cancer Survivorship Research Retreat, 1/2012.
20. Hoffman KE, Kim J, Davis JW, Choi S, Pettaway C, Lee AK, Domain D, Levy L, Madsen LT, Kuban DA. Barriers to Active Surveillance as a Treatment Choice for Prostate Cancer. 25th Annual American Society for Radiation Oncology, Poster Presentation, 10/2011.
21. Domain D, Hoffman KE, Madsen LT, Pettaway CA, Kim J, Davis JW, Lee AK, Pisters L, Levy L, Kuban DA. Clinical Trial Enrollment in a Multidisciplinary Prostate Cancer Clinic. 25th Annual American Society for Radiation Oncology, 10/2011.
22. Hoffman KE, Madsen LT, Levy L, Pettaway C, Pisters L, Choi S, Kim J, Davis JW, Ward JF, Kuban DA. Prostate Cancer Treatment Selection after Counseling in a Multidisciplinary Prostate Cancer Clinic. 25th Annual American Society for Radiation Oncology, 10/2011.
23. Lopez DS, Garoma L, Waring SC, Bondy M, Forman M, Kim J, Strom SS. Relationship of features of metabolic syndrome with prostate cancer in Mexican-Americans. 10th Annual AACR International Conference on Frontiers in Cancer Prevention Research, 10/2011.
24. Aparicio A, Harzstarrtk AL, Lin E, Corn PG, Araujo JC, Tu SM, Pagliaro LC, Millikan RE, Arap W, Kim J, Ryan CJ, Zurita AJ, Tannir NM, Lin AM, Small EJ, Mathew P, Jones DM, Troncoso P, Thall PF, Logothesis C. Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin and docetaxel (CD) and salvage etoposide and cisplatin (EP). 47th American Society of Clinical Oncology, Poster Presentation, 6/2011.
25. Pagliaro LC, Zurita AJ, Araujo JC, Ward JF, Davis JW, Pettaway CA, Tu SM, Kim J, Dieringer P, Logothetis C, Pisters LL. Presurgical docetaxel (Doc) and androgen deprivation therapy (ADT) in lymph node-positive prostate cancer (PCA). 47th American Society of Clinical Oncology, Poster Presentation, 6/2011.
26. Li J, Suraoker M, Tsavachidou D, Menter D, Kim J. Cell type-dependent responses to selenium and knockdown of SBP2. 102nd American Association of Cancer Research, Poster Presentation, 2/2011.
27. Kim J, Davis JW, Ward J, Wang X, Pettaway C, Pisters L, Matin S, Kuban D, Frank SJ, Lee AK, Prokhoroval I, Brown V, Logothetis CJ, Troncoso P. Incidence of reclassification in patients undergoing active surveillance for favorable-risk prostate cancer. 100th United States and Canadian Academy of Pathology, Oral Presentation, 2/2011.
28. Li J, Ding Z, Wang Z, Logothetis C, Mills GB, Kim J. Androgen regulation of 5-reductase isoenzymes in prostate cancer: Implications for prostate cancer prevention. 9th American Association of Cancer Research Frontiers in Cancer Prevention, Poster Presentation, 11/2010.
29. Davis JW, Troncoso P, Ward J, Pettaway C, Pisters L, Kuban D, Brown V, Logothetis C, Kim J. Active surveillance for localized prostate cancer - A prospective protocol. 105th American Urologic Association, Oral Presentation, 4/2009.
30. Parker P, Latini D, Ward J, Pettaway C, Pisters L, Matin S, Frank S, Brown V, Kuban D, Logothetis C, Kim J, Davis J. Association between uncertainty, anxiety, and quality of life in men with prostate cancer on active surveillance. 30th Society of Behavioral Medicine, Oral Presentation, 4/2009.
31. Li J, Mills GB, Lin SH, Huang M, Logothetis CJ, Kim J. Differential and cell type-dependent transcriptional regulation of SRD5A1, SRD5A2, and SRD5A3 in the androgen receptor pathway in prostate cancer. 100th American Association of Cancer Research, Poster Presentation, 4/2009.
32. Davis JW, Troncoso PT, Ward JF, Pettaway CA, Pisters LL, Kuban D, Brown V, Logothetic C, Kim J. Active surveillance for clinically localized prostate cancer at a high volume tertiary referral center. Societe Internationale d'Urologie Oncology Update, 11/2008.
33. Davis JW, Kim J, Troncoso PT. Radical Prostatectomy findings in patients considered potential candidates for active surveillance. Societe Internationale d'Urologie Oncology Update, 11/2008.
34. Davis JW, Troncoso P, Ward J, Babian RJ, Pettaway C, Pisters L, Kuban D, Brown V, Logothetis C, Kim J. Active surveillance for clinically localized prostate cancer in the era of technology: Introduction of a prospective protocol into a high volume tertiary research center. 24th Annual European Association of Urology Congress, Poster Presentation, 2008.
35. Troncoso P, Davis JW, Ward JF, Wang X, Nakanishi H, Babaian RJ, Kim J. Radical prostatectomy findings in patients considered potential candidates for active surveillance. 97th United States and Canadian Academy of Pathology, Abstr #845, Oral Presentation, 2008.
36. Tsavachidou D, McDonnell TJ, Wen S, Wang X, Vakar-Lopez F, Pisters LL, Pettaway CA, Wood CG, Do KA, Thall PF, Stepehns C, Taylor R, Menter DG, Troncoso P, Lippman SM, Logothetis CJ, Kim J. Tissue Effects of Selenium and Vitamin E in Prostate Cancer. Poster Discussion, NCI Translational Science Meeting, 2008.
37. Aparicio AM, Lin AM, Araujo JC, Logothetis CJ, Kim J, Pagliaro LC, Tu S, Guo C, Jones D, Thall P, Mathew P. Use of clinical features to select a chemotherapy-responsive variant of aggressive prostate cancer (PC), Abstract 16000. J Clin Oncology 26, 2008.
38. Suraokar M, Mills M, Kim J, Lippman SM, Menter DG. Conditional inactivation on the mouse SBP2 gene to elucidate the function of selenoproteins in prostate cancer. Proceedings of the American Association for Cancer Research 48, Poster Presentation, 2007.
39. Blando J, Portis M, Benevidas F, Kim J, Mills G, Conti C, Walker CL. PTEN Deficiency is fully penetrant for invasive prostatic carcinoma in C57B1/6 Mice. PI 3-Kinase Signaling Pathways in Disease. Keystone Symposia, Poster Presentation, 2007.
40. Vakar-Lopez F, Kim J, Wang X, Zurita A, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Prokhorova IN, McDonnell TJ, Logothetis CJ, Troncoso P. A preoperative model evaluating the tissue effects of chemopreventive agents in clinically localized prostate cancer. 95th Annual USCAP Meeting, Lab Invest 86:167A, Poster Presentation, 2006.
41. Kim J, Wang X, Babaian R, Pisters L, Pettaway C, Wood C, Sabichi A, McDonnell T, Logothetis C, Troncoso P. A preoperative model evaluating the tissue effects of chemopreventive agents in low-volume prostate cancer. Proceedings of the American Society of Clinical Oncology 42 (abstr 1007) Oral Presentation, 2006.
42. Lin SH, Lee YC, Tu SM, Wen S, Mathew P, Yu-Lee LY, Troncosco P, Kim J, Logothetis C. Evaluating an osteoblast regulator bone-metastasis related factor-1 in patients with prostate cancer. Prostate Cancer Foundation, 13th Annual Scientific Retreat, Poster Presentation, 2006.
43. Kim J, Troncoso P, Coombes K, Logothetis C, McDonnell T. Therapy stratification based on dynamic modulation of genetic networks in patients with low-volume prostate cancer. Inter-Prostate SPORE Meeting (p.46), Poster Presentation, 2006.
44. Tu SM, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin SH, Logothetis CJ. Chronic adverse effects from strontium-89 treatment in patients with androgen-independent prostate cancer and bone metastases. Proceedings of the American Society of Clinical Oncology 41:abstr 4671, 2005.
45. Yang P, Kim J, Chan D, Cartright C, Navone N, Shureiqi I, Newman RA. Defining the role of arachidonate metabolism as an approach for prevention of prostate cancer. 4th American Association of Cancer Research Frontiers in Cancer Prevention Research, Cancer Epidemiol Biomarkers Prev 14 (11 Suppl.):2713S (Abstr. B18), Poster Presentation, 2005.
46. McDonnell TJ, Do KA, Wen S, Troncoso P, Babaian R, Pisters L, Pettaway C, Wood C, Lippman S, Logothetis C, Sabichi A, Xiao L, Zhang L, Kim J. Global gene expression assessment reveal treatment specific and cell type specific responses to selenium and vitamin E in patients with organ-confined prostate cancer. Inter-Prostate SPORE Meeting. Oral Presentation, 2005.
47. Mao S, Daliani D, Wang X, Do KA, Thall PF, Perez CA, Brown MA, Logothetis CJ, Kim J. Phase II randomized, placebo-controlled, double-blind study of IM862 plus a short course of androgen ablation for patients with androgen-dependent prostate cancer who failed local therapies - A platform for new drug screening. Proceedings of the American Society of Clinical Oncology 41:abstr 4684, 2005.
48. Kim J, Vakar-Lopez F, Wang X, Thall P, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, Lieberman R, McDonnell T, Sabichi AL, Logothetis CJ, Troncoso PA. Preoperative Model of Clinically Localized Prostate Cancer: The Devil is in the Details. The 13th SPORE Investigators’ Workshop. Oral Presentation:abstr 220, 2005.
49. Kim J, Vakar-Lopez F, Wang X, Thall P, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, Lieberman R, McDonnell T, Sabichi AL, Logothetis CJ, Troncoso P. A. Preoperative Model of Clinically Localized Prostate Cancer: The Devil is in the Details. The 13th SPORE Investigators’ Workshop. Oral Presentation:abstr 220, 2005.
50. Tu S, Kim J, Pagliaro LC, Vakar-Lopez F, Wong FC, Wen S, General R, Podoloff DA, Lin S, Logothetis CJ. Strontium-89 combined with chemotherapy does not compromise subsequent therapy in selected patients with androgen-independent prostate cancer. Skeletal Complications of Malignancy IV. Poster Presentation:abstr 93, 2005.
51. Suraokar M, Kim J, Llansa N, Mendosa G, Logothetis CJ, Lippman SM, Menter DG. Tetracycline-inducible mouse U6 vector for conditional expression of shRNA. Proceedings of the American Association for Cancer Research 46. Poster Presentation:abstr 5442, 2005.
52. Kim J, Vakar-Lopez F, Thall PF, Wang X, Stephens CL, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Pereira P, Soto C, Menter DG, Lieberman R, McDonnell TJ, Lippman SM, Sabichi AL, Logothetis CJ, Troncoso P. The effects of selenium and vitamin E on apoptosis and proliferation in prostate tissue from a preprostatectomy study in patients with clinically organ-confined prostate cancer. Proceedings of the American Association for Cancer Research 46. Poster Presentation:abstr 1612, 2005.
53. Kim J, Do KA, Wen S, Troncoso P, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Lippman SM, Logothetic CJ, Sabichi AL, Xiao L, Zhang L, McDonnell TJ. A global assessment of gene expression in prostate cancer cells from patients enrolled in a phase IIA, randomized trial of selenium and vitamin E. The 12th SPORE Investigators' Workshop. Poster Discussion:abstr 107, 2004, 2004.
54. Suraokar M, Kim J, Lippman SM, Menter DG. Elucidating the role of selenoproteins in prostate cancer using a novel conditional and inducible lentiviral-based siRNA vector. MD Anderson Trainee Recognition Day & Research Exposition, 2004.
55. Kim J, Yang P, Sabichi AL, Vakar-Lopez F, Llansa N, Mendosa G, Newman RA, Lippman SM, Menter DG. Prostate stromal prostaglandin D2 synthase-derived eicosanoid products suppress prostate cancer cell growth. Proceedings of the American Association for Cancer Research 45. Poster Presentation:abstr 873, 2004.
56. Vakar-Lopez F, Cheng C-J, Kim J, Shi GG, Tunstead JR, Troncoso P, Ruggeri A, Tu S-M, Lin S-H. Up-regulation of soluble ErbB3 in metastatic prostate cancer cells and activated osteoblasts in bone marrow. The 93rd Annual U.S. and Canadian Academy of Pathology Meeting. Poster Presentation:abstr 764, 2004.
57. Lin SH, Kim J, Tunstead J, Chen DT, Luo W, Earley K, and Yu-Lee LY. Effectors of 16-kDa Prolactin in Endothelial Cells. The Endocrine Society's 85th Annual Meeting. Oral Presentation, 2003.
58. Kim J, Troncoso P, Thall PF, Wang X, Llansa N, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Johnson K, Taylor RJ, Menter DG, Lippman SM, Logothetis CJ, Lieberman R, Sabichi AL. Effects of vitamin E and selenium on plasma lipid peroxidation: Preliminary results from a randomized, controlled trial of selenium and vitamin E in preprostatectomy patients. Proceedings of the American Association for Cancer Research 44 (abstr 3905). Poster Presentation, 2003.
59. Mintz P, Kim J, Do KA, Wang X, Zinner RG, Cristofanilli M, Arap MA, Hong WK, Troncoso P, Logothetis CJ, Pasqualini R, Arap W. Fingerprinting the circulating repertoire of antibodies from cancer patients. Proceedings of the American Association for Cancer Research 44 (abstr 5629). Poster Presentation, 2003.
60. Fizazi K, Sikes CR, Yang J, Kim J, Martinez LA, Logothetis CJ, Navone NM. High efficacy of docetaxel in preclinical models of advanced prostate cancer with and without androgen ablation and estramustine. Proceedings of the American Association for Cancer Research 44 (abstr 810). Poster Presentation, 2003.
61. Lin SH, Tu SM, Vakar-Lopez F, Troncoso P, Earley K, Tunstead J, Kim J, Galfione M, McNally FJ, Hu M, Kobayashi R, Logothetis CJ. Identification of bone metastasis-related factors in the bone marrow supernatant from prostatic cancer patients. The IVth International Conference on Cancer-Induced Bone Diseases (p. 42, Oral Presentation Section), 2003.
62. Shi GG, Tu SM, Kim J, Earley K, Wang X, Logothetis C, Lin SH. Platelet-derived growth factor AB and BB in the bone marrow of prostate cancer patients with bone metastasis. The IVth International Conference on Cancer-Induced Bone Diseases (p. 45, Poster Abstracts). Poster Presentation, 2003.
63. Vakar-Lopez F, Cheng CJ, Kim J, Shi GG, Tunstead JR, Troncoso P, Ruggeri A, Tu SM, Lin SH. Up-regulation of soluble ErbB3 in metastatic prostate cancer cells and activated osteoblasts in bone marrow. The IVth International Conference on Cancer-Induced Bone Diseases (p. 19, Poster Abstracts). Poster Presentation, 2003.
64. Tu SM, Kim J, Wang X, Do KA, Earley K, Ruggeri A, Logothetis C, Lin SH. Validating insulin-like growth factor (IGF)-1 and IGF binding protein (IGFBP)-3 as pertinent therapeutic targets for advanced prostate cancer. The IVth International Conference on Cancer-Induced Bone Diseases (p. 50, Poster Abstracts). Poster Presentation, 2003.
65. Kim J, Sabichi AL, Troncoso P, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Thall PF, Johnson K, Menter DG, Lippman SM, Logothetis CJ, Lieberman R. A preoperative model for testing chemopreventive agents in prostate cancer. Proceedings of the American Association for Cancer Research 43:639 (abstr 3174). Poster Presentation, 2002.
66. Kim J, Troncoso P, Menter DG, Babaian RJ, Pisters LL, Pettaway CA, Wood CG, Taylor RJ, Thall PF, Johnson K, Cavazos C, Lippman SM, Logothetis CJ, Lieberman R, Sabichi AL. A preprostatectomy clinical model testing chemopreventive agents in prostate cancer. The 10th SPORE Investigators’ Workshop (abstr 15). Poster Presentation, 2002.
67. Li Z, Amato R, Papandreou C, Pagliaro L, Kim J, Millikan R, Loggins-Coffman J, Perez C, Logothetis C, Daliani D. Phase II study of thalidomide for patients with metastatic renal cell carcinoma (MRCC) progressing after interleukin-2 (IL-2)-based therapy (Rx). Proceedings of the American Society of Clinical Oncology 20:180a (abstr 717). Poster Presentation, 2001.
68. Kim J, Millikan RE, Pagliaro L, Tu SM, Daliani DD, Papandreou C, Amato RJ, Logothetis C. Phase II trials of continuous intravenous infusion of interleukin-2 for refractory metastatic urothelial carcinoma. Proceedings of the American Society of Clinical Oncology 19:353a (abstr 1388). Poster Presentation, 2000.
69. Kim J, Diaz M, Logothetis CJ, Hoosein NM. Expression of prolactin and prolactin receptors by human prostatic cancer cell lines, PC-3, DU-145 and LNCaP. Proceedings of the American Association for Cancer Research 39:110 (abstr 746), Poster Presentation, 1998.
70. Kim J, Finn L, Hodges S, Hoosein N, Deftos L, Logothetis C. Neuroendocrine marker as a predictor of early progression in androgen-independent prostate cancer (AIPC). ). Proceedings of the American Society of Clinical Oncology 34:315a (abstr 1213). Poster Presentation, 1998.

Book Chapters

1. Logothetis CJ, Kim J, Davis JW, Chapin BF, Kuban DA, Efstathiou E, Aparicio A. Neoplasms of the Prostate. In: Holland-Frei Cancer Medicine. B C Decker Inc, 9th Edition. In Press.
2. Parker PA, Kim J, Latini DM. Patient Support Intervention. In: Robot-Assisted Radical Prostatectomy: Beyond the Learning Curve. Springer. In Press.
3. Patterson ML, Davis JW, Kim J, Hoffman KE, Osai WE, Kuban DA. Genitourinary Cancer Survivorship Management. In: Advances in Cancer Survivorship Management. Ed(s) Foxhall LE, Rodriguez MA. Springer: New York, NY, 95-104, 2014.
4. Logothetis CJ, Troncoso P, Kim J, Davis JW, Kuban DA, Mathew P, Aparicio A. Neoplasms of the Prostate. In: Cancer Medicine, 8th. Peoples Medical Publishing House-USA: Shelton, CONN, 1228-54, 2010.
5. Zurita AJ, Ward JF, Kim J. Targeted therapy in prostate cancer. In: R Kurzrock, Markman (ed): Targeted Therapy in Cancer Humana Press USA, 2007, 289-304, 2008.
6. Kim J, Logothetis C. A biological framework for the development of therapy in prostate cancer. In: Progress in Anti-Cancer Chemotherapy. Springer-Verlag, 189-201, 2000.

Letters to the Editor

1. Kim J, Amos C, Logothetis C. Prostate Cancer Prevention: Does Caution Threaten Progress? New Eng J Med 365(24):2340, 12/2011. PMCID: PMC22168662.

Manuals, Teaching Aids, Other Teaching Publications

1. Online Video Education, Prostate Survivorship Course: Active Surveillance, 2012.
2. Kim J. Standard Operations Manual, Genitourinary Medical Oncology Serum Bank, 2000.
 

Other

1. UT MD Anderson Website and Local T.V. Video.

Grant & Contract Support

Title: Genetic Susceptibility and Biomarkers of Platinum-related Toxicities
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Lois Travis, MD
Duration: 8/1/2015 - 7/31/2017
 
Title: Metabolic Profiling of Core Biopsies from Finasteride Exposed and Unexposed Early Stage Prostate Cancer: Toward Risk Stratification by In Vivo Metabolic Imaging
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Bhattacharya
Duration: 10/1/2013 - 1/31/2015
 
Title: Cancer Prevention Agent Development Program: Early Phase Clinical Research
Funding Source: NIH/NCI
Role: Collaborator
Principal Investigator: Powel Brown
Duration: 9/1/2012 - 8/31/2019
 
Title: Patient education for prostate cancer patients on active surveillance
Funding Source: Tex US TOO, Inc.
Role: Collaborator
Duration: 2011
 
Title: MD Anderson Cancer Center Prostate SPORE. Project 5: MicroRNA in Prostate Cancer Progression: Genetic Variation, Genotype-Phenotype Correlation, and Circulating Biomarker
Funding Source: NIH/NCI
Role: Clinical Co-Leader
Principal Investigator: Christopher Logothesis
Duration: 9/2/2009 - 8/31/2014
 
Title: The University of Texas M.D. Anderson SPORE in prostate cancer, Specimen Core C
Funding Source: NIH/NCI
Role: Collaborator
Duration: 9/2/2009 - 8/14/2014
 
Title: A randomized controlled trial evaluating the tissue effects of preoperative finasteride versus placebo for patients with clinically organ-confined prostate cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2007 - 2013
 
Title: An animal model for adverse progression of prostate cancer, The University of Texas MD Anderson SPORE in Prostate Cancer
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 1/12/2006 - 12/31/2007
 
Title: Collaboration between Royal Marsden NHS Trust/Institute of Cancer Research and The University of Texas MD Anderson Cancer Center through Establishment of Postdoctoral Fellowship, 1-Selenomethionine, alpha-tocopherol, and oxidative stress: their effects on cell death and gene regulation in prostate cells
Funding Source: The Kadoorie Charitable Foundation
Role: Collaborator
Duration: 2003 - 2007
 
Title: Differential gene expression induced by antioxidants, National Cancer Institute
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2003 - 2007
 
Title: Modulation of the arachidonic acid cascade by l-selenomethionine and alpha-tocopherol in normal and malignant prostate cells, The University of Texas MD Anderson SPORE in Prostate Cancer Career Development Award
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2003 - 2005
 
Title: The University of Texas MD Anderson SPORE in Prostate Cancer, Tissue Resource & Pathology Core
Funding Source: NIH/NCI
Role: Co-Investigator
Duration: 2001 - 2007
 
Title: Fingerprinting the circulating pool of tumor-related antibodies in cancer patients: Translation into clinical application
Funding Source: Clinician Investigator Career Development Program
Role: Principal Investigator
Duration: 2001 - 2004
 
Title: Development of in situ expression of the 16K fragment of prolactin with antiangiogenic activity for prostate cancer treatment.
Funding Source: Institutional Research Grant Award
Role: Principal Investigator
Duration: 2001 - 2003
 
Title: Fingerprinting the circulating pool of tumor-related antibodies from prostate cancer patients, CaP CURE Research Award
Funding Source: CaP Cure Research Award
Role: Co-Investigator
Duration: 2001 - 2002
 
Title: A feasibility study of l-selenomethionine and alpha-tocopherol in prostate cancer
Funding Source: NIH/NCI
Role: Principal Investigator
Duration: 2000 - 2005

Last updated: 9/10/2016